Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Sep;53(9):1366-73.
doi: 10.1136/gut.2003.025452.

Biologics in inflammatory bowel disease: how much progress have we made?

W J Sandborn  1 , W A Faubion
Affiliations
Review

Biologics in inflammatory bowel disease: how much progress have we made?

W J Sandborn et al. Gut. 2004 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of response according to the concentration of antibodies against infliximab before infusion. Box plots show median values and first and third quartiles in each group. The T bars represent the rest of the data with a maximum of 1.5 times the interquartile range. The four categories can be divided in two groups: the first two categories have concentrations of antibodies against infliximab of <8.0 µg/ml and the second two have concentrations ⩾8.0 µg/ml. Median duration of response in the first two groups differed significantly (p<0.001) from the median duration of response in the groups with titres of ⩾8.0 µg/ml. Reprinted with permission from Baert and colleagues.
Figure 2
Figure 2
Suggested treatment algorithm for managing patients with refractory Crohn’s disease. 6MP, 6-mercaptopurine; AZA, azathioprine; MTX, methotrexate. Modified with permission from: Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68–82.
See this image and copyright information in PMC

Comment in

References

    1. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997;40:443–8. - PMC - PubMed
    1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–35. - PubMed
    1. van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apopotosis in lamina propria T-lymphocytes from patients with Crohn’s diseease. Gastroenterology 2003;124:1774–85. - PubMed
    1. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405. - PubMed
    1. Mayer L , Han C, Bala M, et al. Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohn’s disease (CD). Am J Gastroenterol 2001;96:S303.

MeSH terms